✦ LIBER ✦

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062

✍ Scribed by Mary E.R. O’Brien; Krzystof Konopa; Paul Lorigan; Lionel Bosquee; Ernest Marshall; Frederique Bustin; Sabine Margerit; Christian Fink; Jos A. Stigt; Anne Marie C. Dingemans; Baktiar Hasan; Jan Van Meerbeeck; Paul Baas

Book ID: 116430783
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 277 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.05.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-560 Phase I-II study of amrubicin and

P-560 Phase I-II study of amrubicin and cisplatin as first-line treatment in patients with extensive stage small cell lung cancer (ED-SCLC)

✍ Matsui, Kaoru; Ohe, Yuichiro; Negoro, Shunichi; Nakagawa, Kazuhiko; Sugiura, Tak 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 374 KB

Randomised Phase II study of topotecan/c

Randomised Phase II study of topotecan/cisplatin versus topotecan/etoposide in patients with untreated, extensive disease, small cell lung cancer (SCLC)

✍ Gervais, R; Quoix, E; Mattson, K; Schramel, F.M; Rivière, A; Fields, S; Wheatley 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB

O-279 A multicenter randomised phase II

O-279 A multicenter randomised phase II study of cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as first line treatment in patients with small cell lung cancer (SCLC): Preliminary results

✍ De Marinis, Filippo; Gridelli, Cesare; Lombardo, Marco; Paoluzzi, Luca; Ferraù, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 339 KB

Phase II study of combined belotecan and

Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer

✍ Junshik Hong; Minkyu Jung; Yu Jin Kim; Sun Jin Sym; Sun Young Kyung; Jinny Park; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 284 KB

A multicenter randomized phase III study

A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)

✍ Mavroudis, D; Papadakis, E; Veslemes, M; Agelidou, M; Tsiafaki, X; Agelidou, G; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 103 KB

A multicenter, randomized, Phase II stud

A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma

✍ Filippo De Marinis; Fabrizio Nelli; Marco Lombardo; Francesco Ferraú; Santi Barb 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and toxicity of combined cisplatin, etoposide, and gemcitabine (PEG) and combined cisplatin plus gemcitabine (PG) in previously untreated patients with extensive‐stage and poor‐prognosis limited‐stage small‐cell lun